Michigan's medical marijuana market is, for all practical purposes, gone. The state's licensed medical facilities recorded just $322,350 in total sales during May 2026 - a number so small it barely registers against the adult-use market's $250-plus million in the same month. Yet a federal proceeding scheduled to begin June 29 places marijuana's medical legitimacy at the center of a debate that could have far larger consequences for cannabis businesses across Michigan, Ohio, and every other regulated state in the country.
The National Organization for the Reform of Marijuana Laws filed a formal request this week asking the Drug Enforcement Administration to reconsider who gets to participate in its upcoming marijuana rescheduling hearing - a proceeding that will determine whether cannabis stays classified as a Schedule I controlled substance or moves to Schedule III. The distinction matters enormously for dispensary operators, multi-state companies, and cannabis-adjacent businesses alike. For context on how other state-regulated markets are managing parallel pressures around taxation, compliance, and market structure, read more about Illinois's adult-use framework and what it reveals about the economics of regulated cannabis retail. NORML's core argument is that the DEA's selected participants skew heavily toward rescheduling opponents, effectively sidelining the patients, physicians, and licensed operators whose businesses are most directly affected by the outcome.
Here's the catch: even if you strip away the policy arguments, the proceeding is fundamentally a tax story. Cannabis businesses operating under Schedule I are subject to IRS Section 280E, a federal tax provision that bars companies from deducting ordinary business expenses - payroll, rent, utilities, insurance, marketing - before calculating taxable income. Every other regulated industry deducts those costs. Cannabis operators generally cannot. The result is effective tax rates that can dwarf those paid by comparable businesses in retail, hospitality, or food service. Moving marijuana to Schedule III would not, by itself, legalize cannabis federally or override state adult-use laws. But it would largely eliminate 280E's application, which is why the rescheduling question is being watched closely by accountants, CFOs, and investors across the industry - not just policy advocates.
Michigan's Medical Market Tells a Cautionary Story
The numbers from Michigan's medical program are striking. Before recreational sales launched in December 2019, the state's medical program had more than 300,000 registered patients - one of the largest in the nation. Today, for every dollar spent on medical marijuana in Michigan, consumers are spending roughly $775 on adult-use products. That ratio says everything about what happens to a medical-only framework once recreational access becomes available, competitively priced, and widely distributed.
The practical implication for Michigan operators is that the federal rescheduling debate is no longer primarily a medical market issue - it's a business cost issue. The state's cannabis retailers and cultivators are overwhelmingly serving adult-use consumers. What they want from the federal proceeding is not expanded recognition of marijuana's therapeutic applications; they want relief from a tax structure that treats their payroll costs and utility bills as non-deductible. That's a straightforward financial pressure, and it compounds already thin margins in a market where wholesale cannabis prices have been under sustained downward pressure for several years.
Ohio's Position Adds a Different Dimension
Ohio presents a meaningfully different picture. The state maintains a substantial medical marijuana patient base - more than 459,000 registered patients as of 2025 - alongside its newer recreational market. With 165 dual-use dispensary certificates of operation allowing retailers to serve both populations, Ohio operators have a direct stake in how federal policy treats medical cannabis specifically.
That matters because the entire legal basis for rescheduling rests on the federal government's acceptance of marijuana's medical utility. The U.S. Department of Health and Human Services concluded in 2023 that cannabis has accepted medical uses and recommended the Schedule III move. Ohio's continuing medical program is real, active, and substantial - which means the medical legitimacy argument at the center of the DEA hearing is not academic for Ohio operators. It's the foundation their dual-use business model is built on.
In practice, though, both Michigan and Ohio operators share the same 280E problem regardless of whether they serve medical patients, recreational consumers, or both. Any Schedule III reclassification would affect the entire legal cannabis industry - and the businesses that supply, finance, insure, and build technology for it.
A Proceeding That May Already Be Running Behind Industry Needs
NORML's filing argues that the DEA's witness selection creates the appearance of a predetermined outcome. The DEA has not indicated publicly whether it will revise the participant list before June 29. Legal experts widely expect that whatever comes out of the hearing will face additional procedural challenges and litigation before any final rescheduling rule takes effect - meaning relief from 280E, if it comes at all, is likely still years away.
For dispensary operators managing thin margins, compliance costs, and point-of-sale tax calculations that already reflect 280E's constraints, that timeline is the most consequential fact in this story. The hearing is a step in a long process, not an immediate change to anyone's tax bill. What it does, in the near term, is keep the rescheduling question open and politically visible - which affects investor confidence, M&A activity, and banking access across the sector. Cannabis businesses have operated for years under a federal framework designed for illegal drug trafficking. Whether the June hearing moves that framework meaningfully, or just generates another round of litigation, is the question every CFO and compliance officer in Michigan and Ohio is watching.
